{
    "Case ID": "044896",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent validity and infringement"
    ],
    "Legal_Issue": [
        "Validity of the '203 Patent', utility, sound prediction, adequacy of disclosure"
    ],
    "Governing_Law": [
        "Patent Act"
    ],
    "Procedural_Stage": [
        "Trial"
    ],
    "Evidence_Assessment": [
        "Expert testimonies, testing data on kinase inhibition by Group 2 compounds including imatinib"
    ],
    "Decision_Outcome": [
        "Claims 5, 7, 29, 44, and 46 upheld as valid; Claims 1-4 invalidated"
    ],
    "Burden_of_Proof": [
        "On challenger to prove invalidity; patentee to demonstrate utility or sound prediction"
    ],
    "Credibility_Factor": [
        "Expert testimony and experimental data credibility"
    ],
    "Legal_Rule": [
        "A patent must describe a new and useful invention; utility can be demonstrated or soundly predicted; disclosure must be adequate"
    ],
    "Standard_of_Review": [
        "Legal sufficiency of utility and disclosure under patent law"
    ],
    "Procedural_Issue": [
        "Consolidation of actions by Teva and Apotex"
    ],
    "Grounds_for_Claim": [
        "Lack of utility and insufficient disclosure for broad claims"
    ],
    "Outcome_on_Merits": [
        "Partial success for Novartis; narrow claims valid, broad claims invalid"
    ],
    "Decision_Maker": [
        "Trial court"
    ],
    "Judicial_Review_Outcome": [
        "Not applicable â€“ trial level decision"
    ],
    "Review_Standard": [
        "Statutory interpretation and factual assessment under Patent Act"
    ],
    "Procedural_Fairness_Assessment": [
        "Fair hearing with presentation of expert evidence and data"
    ],
    "Key_Evidence_Considered": [
        "Testing results showing selective kinase inhibition, compound structure data, pharmacological profiles"
    ],
    "Legal_Framework": [
        "Canadian Patent Law"
    ],
    "Applicant_Challenge": [
        "Teva and Apotex challenged validity of '203 Patent"
    ],
    "Court_Result": [
        "'203 Patent valid for imatinib-specific claims; broader claims invalid"
    ],
    "Legal_Rule_Source": [
        "Patent Act, case law on sound prediction and utility"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Argued lack of utility and inadequate disclosure for all claimed compounds"
    ],
    "Evidence_Type": [
        "Scientific data, expert reports, patent documentation"
    ],
    "Remedy_Requested": [
        "Declaration of patent invalidity, right to market generic imatinib"
    ],
    "Outcome": [
        "Generic manufacturers permitted to proceed with regulatory processes; Apotex inventory exempt from seizure"
    ],
    "Decision_Authority": [
        "Trial Court"
    ],
    "Remedy_Sought": [
        "Market access for generic imatinib"
    ],
    "Resolution_Mechanism": [
        "Judicial trial with evidentiary hearings"
    ],
    "Legal_Provision": [
        "Patent Act provisions on utility, novelty, and disclosure"
    ],
    "Authority": [
        "Canadian courts"
    ],
    "Claimant_Status": [
        "Novartis (patent holder), Teva and Apotex (generic applicants)"
    ],
    "Legal_Provision_Cited": [
        "Patent Act, sections relating to utility and disclosure"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Invalidity due to lack of utility and insufficient disclosure"
    ],
    "Applicable_Process": [
        "Litigation under patent challenge framework"
    ],
    "Outcome_of_Review": [
        "Patent upheld in part"
    ],
    "Pending_Relief_or_Application": [
        "Regulatory approval for generic drug marketing"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Patent Act requirements for valid patent grant"
    ]
}